Pancreatic Cancer Research

ResearcherInstituto de Investigación Sanitaria del Hospital Clínico San CarlosActive in the last 2 years

María Jesús Fernández‐Aceñero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2439-3553; OpenAlex author ID A5091662927, A5121150265. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study. First author DOI 10.1093/ajcp/aqag037↗
  2. FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer Co-author DOI 10.1101/2025.09.12.675778↗
  3. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  4. Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest. Co-author DOI 10.1002/1878-0261.13616↗
  5. DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11102812↗
  6. The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. Co-author DOI 10.3390/jcm9051252↗
  7. Still a place for conventional histopathological analysis in the era of molecular medicine: predicting prognosis of resectable ductal pancreatic adenocarcinoma. Co-author DOI 10.1007/s12094-018-02008-4↗
  8. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Co-author DOI 10.1007/s12253-017-0341-0↗
  9. The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. Co-author DOI 10.3390/jcm8091275↗
  10. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. Co-author DOI 10.1371/journal.pone.0182044↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Javier Martínez‐Useros · 9 shared papers, 2017–2026 · strength 1.38
  2. Jesús García‐Foncillas López · 7 shared papers, 2017–2025 · strength 0.97
  3. Michael Ochieng’ Otieno · 2 shared papers, 2023–2025 · strength 0.44
  4. Carlos Lacalle-González · 2 shared papers, 2023–2025 · strength 0.44
  5. Weiyao Li · 4 shared papers, 2017–2020 · strength 0.36
  6. Ana María Colino Gallardo · 1 shared paper, 2026 · strength 0.32
  7. Carlos Lopez-Blazquez · 1 shared paper, 2025 · strength 0.26
  8. Nuria Garcia-Carbonero · 2 shared papers, 2019–2020 · strength 0.20
  9. Aiora Cenigaonandia‐Campillo · 1 shared paper, 2024 · strength 0.17
  10. Óscar Aguilera · 1 shared paper, 2024 · strength 0.17
  11. Katja Peschke · 1 shared paper, 2025 · strength 0.16
  12. Katrin J. Frank · 1 shared paper, 2025 · strength 0.16
  13. Jiaoyu Ai · 1 shared paper, 2025 · strength 0.16
  14. Derya Bakırdöğen · 1 shared paper, 2025 · strength 0.16
  15. Marina Lesina · 1 shared paper, 2025 · strength 0.16
  16. Kıvanç Görgülü · 1 shared paper, 2025 · strength 0.16
  17. Nan Wu · 1 shared paper, 2025 · strength 0.16
  18. Sonia Alcalá · 1 shared paper, 2025 · strength 0.16
  19. Raphela A. Ranjan · 1 shared paper, 2025 · strength 0.16
  20. Maximilian Reichert · 1 shared paper, 2025 · strength 0.16
  21. Harun Öztürk · 1 shared paper, 2025 · strength 0.16
  22. Juan Carlos López-Gil · 1 shared paper, 2025 · strength 0.16
  23. Roland Michael Schmid · 1 shared paper, 2025 · strength 0.16
  24. Dietrich Alexander Ruess · 1 shared paper, 2025 · strength 0.16
  25. Mazhar Adli · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.